Research programme: BMX protein inhibitors - SuperGen
Latest Information Update: 26 Sep 2011
At a glance
- Originator SuperGen
- Developer Astex Pharmaceuticals
- Class Small molecules
- Mechanism of Action BMX protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer